Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-05-17
2005-05-17
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S025000, C436S063000, C436S071000
Reexamination Certificate
active
06893829
ABSTRACT:
The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics.
REFERENCES:
patent: 4849445 (1989-07-01), Schaub
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5238832 (1993-08-01), Johnson et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5250565 (1993-10-01), Brooks et al.
patent: 5686496 (1997-11-01), Anderskewitz et al.
patent: 5731332 (1998-03-01), Anderskewitz et al.
patent: 5795914 (1998-08-01), Konno et al.
patent: 5861268 (1999-01-01), Tang et al.
patent: 6046224 (2000-04-01), Natarajan et al.
patent: 9405777 (1994-03-01), None
patent: 9518609 (1994-07-01), None
HCAPLUS abstract AN 1988:543217 (1988) Natarajan et al.*
HCAPLUS abstract AN: 1995: 245416 (1994) Alanko, J. et al.*
HCAPLUS abstract AN 1989: 451108 (1989) Ibe, B. et al.*
Branch TI BS 23: 45-50, 1998.*
D. W. Foster, In R.G. Petersdorf (ED), Harrison's Principles of Internal Medicine, Morgan Hill, 1983, pp. 661-669.*
G. Wolf et al, Biochem, Biophys. Res. Commun., 176, 902-909, 1991.*
M. Kihara et al, Chem. Abst., 115, 85182 b, 1991.*
M. Itakura et al, Chem. Abst., 115, 1501312, 1991.*
E. N. Ellis et al, Chem. Abst, 115, 150134d, 1991.*
H. P. Hammes et al, Chem Abst. 115, 991462, 1992.*
J. A. Corbett, et al Chem Abst. 115, 249200t, 1992.*
R. Natarajan et al., “Tumor Necrosis Factor and Interleukin-1 are Potent . . . Synthesis”, Endocrinology, vol. 125, No. 6, Dec. 1989, 3084-3089.
R. Natarajan et al., “Vascular Smooth Muscle Cells Exhibit . . . Glucose”, Biochem. & Biophys. Res. Comm., vol. 187, No. 1, Aug. 31, 1992, 552-560.
R. Natarajan et al., “Mechanism of Angiotensin-II-Induced . . . Cells”, Endocrinology, vol. 131, No. 3, Sep. 1992, 1174-1180.
C.P. Bell-Quilley et al., “Renovascular Actions of . . . Lipoxygenases”, Journal of Pharm. & Exper. Thera., vol. 267, No. 2, Nov. 1993, 676-682.
J.A. Kim et al., “Evidence that a Leukocyte Type of . . . Cells”, Clinical Research, vol. 41, No. 2, (1993), 148A.
E. Sigal et al., “Molecular Cloning and Primary . . . 15-Lipoxygenase”, Biochem. & Biophys. Res. Comm., vol. 157, No. 2, Dec. 15, 1988, 457-464.
Rama Natarajan et al., “Elevated Glucose and Angiotersin II . . . Smooth Muscle Cells,” Proc. Natl. Acad. Sci., vol. 90, pp. 4947-4951 (Jun. 1993).
Jai-Li Gu et al., “Evidence that a Leukocyte Type of . . . Adrenal Glomerulosa Cells,” Endocrinology, vol. 134, No. 1, pp. 70-77 (Jan. 1994).
David Bleich et al., “Interleukin-1β Regulates the Expression of . . . and RIN m5F Cells.” Endocrinology, vol. 136, No. 12, pp. 5736-5744 (Dec. 1995).
Balt et al. “2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity”J. Med. Chem. 33:360-370 (1990).
Bleich et al. “The stress-activated c-jun protein kinase (JNK) is stimulated by lipoxygenase pathway product 12-HETE in RIN m5F cells”Biochem. Biophys. Res. Commun, 230:448-451 (1997).
Cho et al.,J. Med. Chem, 34:1503-1505 (1991).
Gorins et al.J. Med. Chem. 39:4871-4878 (1996).
Hajjar, D.P. et al., “Signal Transduction in Atherosclerosis: Integration of Cytokines and the Eicossanoid Network”FASEB J. 6:2933-2941 (Aug. 1992).
Honn et al.,Cancer Metastasis Rev. 13:365-396 (1994).
Jost-Vu, E. et al.,Clin. Res. 40:106 (abstr.) (1992).
Larrue, J., et al.,Biochem. Biophys. Res. Commun. 112: 242-49 (1983).
Li, Maher, Schubert“A Role for 12-Lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion”Neuron19:453-463 (1997).
Liu et al. “Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C”Cell Regulation2:1045-1055 (Dec. 1991).
Metz, S. et al.,Proc. Natl. Acad. Sci. USA 82:198-202 (1985).
Nadler, J.L., et al., “Specific Action of the Lipoxygenase Pathway in Mediating Angiotensin II-induced Aldosterone Synthesis in Isolated Adrenal Glomerulosa Cells”J. Clin. Invest. 80:1763-1769 (Dec. 1987).
Natarajan, R., et al.,Hypertension 23(Supp. I):I142-I147 (1994).
Natarajan, R., et al.,J. Clin. Endocrinol. Metab. 67:584-591 (1988).
Natarajan et al., “Arachidonic Acid Metabolities on Renin and Vascular Smooth Muscle Cell Growth” Chapter 26 in: Contemporary Endocrinology: Endocrinology of the Vasculature (Sowers Ed.) Humana Press, Inc., Totowa, NJ, pp. 373-387, (6/96).
Natarajan, Bai, Lanting, Gonzales, Nadler “Effects of High Glucose on Vascular Endothelial Growth Factor Expression in Vascular Smooth Muscle Cells”Am. J. Physiol. 273 (Heart Circ. Physiol. 42):H2224-H2231 (1997).
Natarajan et al. “Role of 12-lipoxygenase in angiotensin II-induced proliferationin adrenal cells”Clinical Research39(2):184A (1991).
Nishio et al., “Role of the lipoxygenase pathway in phenylephrine-induced vascular smooth muscle cell proliferation and migration”European J. of Pharmacology336:267-273 (1997).
Nozawa et al.Am. J. Physiol. 259:H1447-H1780 (1990).
Parthasarathy, S. et al.,Proc. Natl. Acad. Sci. USA 86:1046-1050 (1989).
Rao, G.N., et al.,Oncogene(1993) 8:2759-2764.
Stern, N., et al., “Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade”Am. J. Physiol. 257:H434-H443 (1989) (Abstr.).
Wen et al., “Evidence that angiotensin II and lipoxygenase products activate c-jun NH2-terminal kinase”Circ. Res. 81:651-655. (1997).
Wen et al.,Am. J. Physiol, 271 (Cell Physiol. 40): C1212-C1220 (1996).
Yu, C.L., “Serum Stimulation of NIH 3T3 Cells Induces the Production of Lipids Able to Inhibit GTPase-Activating Protein Activity”Mol. Cell Biol. 10:6683-6689 (1990).
Johnson et al., “Antioxidant With marked Lipid- and Glucose-Lowering Activity in Diabetic Rats and Mice”, Diabetes, vol. 42, Aug. 1993 1179-1186.
Nadler Jerry L.
Natarajan Rama
City of Hope
Rothwell Figg Ernst & Manbeck
LandOfFree
Human leukocyte 12-lipoxygenase and its role in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human leukocyte 12-lipoxygenase and its role in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human leukocyte 12-lipoxygenase and its role in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409643